Scientific Sessions 2026 Daily News: Monday, Nov. 9

4 SCIENTIFIC SESSIONS DAILY NEWS | Monday, Nov. 9, 2026 good efficacy and safety across the various stroke subtypes,” Sharma said. “It’s not the case that one has to think very hard about what the patient’s risk is and what exactly the risk factors are before determining eligibility for asundexian. It seems to work well across a number of risk strata. The major clinical implication is that it is easy to use for a wide variety of patients.” Asundexian is the FXIa inhibitor to reach phase 3 trials. A second agent, milvexian, may report topline phase 3 results in early 2027. “This is the first agent in the class, and I expect it to have an effect on guidelines,” Sharma said. “If there are two trials, both of which show similar results, it becomes much easier for guideline writers to revisit secondary stroke prevention.” Asundexian is the first FXI/FXIa inhibitor to reach phase 3 trials. A second agent, milvexian, may report top line phase 3 results in early 2027. “This is the first agent in the class and I expect it to have an effect on guidelines,” Sharma said. “If there are 2 trials, both of which show similar results, it becomes much easier for guideline writers to revisit secondary stroke prevention.” Spironolactone-based treatment lowered post-stroke blood pressure nearly 8 mmHg vs. usual care Hypertension is the leading modifiable risk factor for recurrent stroke, yet post-stroke blood pressure control remains suboptimal. A randomized, open-label trial comparing spironolactone-containing blood pressure regimens following ischemic stroke or intracerebral hemorrhage (ICH) found clinically significant and durable reductions in home blood pressure compared to usual care. Initial results of the “Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke (REDUCE) Trial” showed a mean difference in home systolic blood pressure of 7.7 mmHg at three months and 6.9 mmHg at six months compared to standard care. “These were not patients with resistant hypertension; these were people who, at baseline, were on an average of two antihypertensive medications,” said Jordana Cohen, MD, MSCE, FAHA, associate professor of medicine and epidemiology at the University of Pennsylvania Perelman School of Medicine in Philadelphia “There is a lot to be said for the benefit of blocking aldosterone post-stroke. Historically, spironolactone is something we sometimes use as our fourth drug, but we may want to be thinking about it as a second or third drug post-stroke.” Jordana Cohen, MD, MSCE, FAHA REDUCE randomized 160 patients following ischemic stroke or ICH across five U.S. centers to either a spironolactone-based blood pressure regimen (85 patients) or standard care (75 patients), in which treating clinicians received a letter summarizing 2017 ACC/ AHA high blood pressure guideline recommendations for stroke survivors. The mean age of trial participants was 63 years; 37% were female and 29% Black; 54% had ICH and 46% had ischemic stroke. The mean baseline systolic blood pressure was 136 mmHg, and participants were taking a mean of two antihypertensive medications. The primary outcome was home systolic blood pressure (SBP) at three months. Secondary outcomes included home diastolic blood pressure (DBP) at three months, home SBP/DBP at six months, the number of concomitant antihypertensive medications at three months and the proportion achieving blood pressure target of <130/80 mmHg at three months. At three months, the spironolactone group had a mean SBP of 125.6 mmHg vs. 133.3 mmHg for standard care, a mean difference of -7.7 mmHg (95% CI: [-11.6, -3.8], p=0.0002). The difference was similar at six months: 124.0 vs. 130.9 mmHg, a mean difference of -6.9 (95% CI: [-10.6, -3.2], p=0.0004). Participants in the spironolactone group were taking more antihypertensive medications at 3 months, including spironolactone: 2.6 vs. 2.1, for a mean difference of 0.5 (95% CI: [0.2, 0.9], p=0.004). Serious adverse event rates were similar: 15% for spironolactone vs. 16% for standard care. Spironolactone showed higher rates of hypotension (8% vs. 1%), lightheadedness (5% vs. 1%) and hyperkalemia (4% vs. 0%) vs. STROKE continued from page 1 Delta Dental is proud to collaborate with the American Heart Association’s Healthy Smiles, Healthy Hearts Initiative. Delta Dental is a registered trademark of Delta Dental Plans Association. Expand Your Understanding of the Dynamic Connection Between Oral and Cardiovascular Health Access our vodcast series, eModule, and other resources bringing the latest science and evidence-based strategies for you to learn about topics like patient safety, accurate blood pressure measurement, and how oral health can be associated with increased risk for cardiovascular disease and stroke risk. Multiple CE credits available, including ADA CERP. American Heart Association. Unauthorized use prohibited. WF-1928217 10/26 LEARN NOW PAID ADVERTISEMENT

RkJQdWJsaXNoZXIy MjI2NjI=